Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa

Core Insights - Sol-Gel Technologies, Ltd. has entered into six exclusive license agreements for the commercialization of its dermatology products TWYNEO and EPSOLAY across multiple European countries, indicating strong market expansion potential [8][9] - The company is focused on developing innovative treatments for skin diseases, with TWYNEO approved for acne vulgaris and EPSOLAY approved for inflammatory lesions of rosacea [3][9] - Sol-Gel is conducting a Phase 3 clinical trial for SGT-610, a treatment for Gorlin syndrome, which is expected to enhance its competitive position in the dermatology market [8][10] Company Overview - Sol-Gel Technologies specializes in identifying, developing, and commercializing drug products for skin diseases, with a focus on innovative formulations [3][8] - The company has developed TWYNEO, a unique topical cream combining tretinoin and benzoyl peroxide, and EPSOLAY, which utilizes a patented technology for encapsulating benzoyl peroxide [2][9] - The company’s pipeline includes additional clinical trials for SGT-610 and SGT-210, targeting rare skin conditions and aiming for improved safety profiles [10] Market Expansion - The new license agreements cover major European markets including Germany, the UK, France, and others, reflecting a strategic move to enhance product availability [8][9] - Sol-Gel is set to receive upfront and regulatory milestone payments totaling up to low 7-digit USD, along with future royalties from net sales, backed by commitments to minimum annual sales [8][9] - The regulatory submissions in these territories will be managed by Sol-Gel's partners, with the company providing assistance in the preparation of these submissions [8]